SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the dominant focus, with traders awaiting confirmation of the 80th death that triggers final analysis; the last disclosed count was 78, and speculation links the prolonged wait and company silence to possible ASH disclosures. Bulls interpret the delay as a potential sign of longer survival, while bears question the trial timeline and warn that the outcome remains uncertain; the debate accompanies a sharp share-price decline.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data on Iovances lifileucel program is the main focus, especially mature frontline melanoma results for lifileucel plus pembrolizumab and early sarcoma findings. Traders highlight durable melanoma responses as supportive of expansion into earlier treatment, while others caution that the cohorts are small and the sarcoma response rate eased as the sample grew.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A Nasdaq-futures rebound around the 1987 Black Monday anniversary is dominating discussion after a steep tech-led selloff, with big-tech earnings ahead. Traders are split on whether the bounce is a durable recovery or a short-covering rally that could fade, while AI-stock weakness and broader market risks remain concerns.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A broad selloff in AI neocloud stocks, driven by worries about debt, financing costs, and whether rapid data-center spending can earn adequate returns, has weighed on Nebius alongside peers. Traders are divided: bears see further valuation pressure, while bulls argue Nebius is better positioned than more leveraged rivals and view the drop as an overdone sector-wide move.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after last weeks tech-led selloff has shifted the conversation to whether the bounce will hold, amid fears tied to the Black Monday anniversary. Bulls call it a relief rally or short squeeze and dismiss crash worries, while skeptics warn the move may fade; upcoming megacap earnings add to market focus.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Lingering concerns over weak guidance, slowing ad-spend growth, and competition in digital advertising are weighing on Trade Desk shares. Traders remain divided between expecting further declines until growth and execution improve and viewing the selloff and high short interest as a potential setup for a rebound.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Concern over IPO lockup expirations and the potential for insider-share selling is a recurring focus as CBRS faces a steep decline. Traders also point to weakness across AI and semiconductor stocks and question the companys high valuation, growth prospects, and reliance on OpenAI; others argue the selloff is overdone and are buying the dip.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is drawing attention amid a sharp, extended semiconductor selloff, with traders questioning whether heavy AI infrastructure spending can deliver sufficient returns and citing inflation, rates, and competitive pressures as additional headwinds. The community is split between expecting an oversold bounce and warning that the pullback could deepen into a broader correction.

Direxion Shares ETF Trust - Direxion Daily MU Bull 2X ETF

Direxion Daily MU Bull 2X Shares

MUU is drawing attention after a sharp selloff alongside Micron and other memory stocks, with traders debating whether the drop is a dip-buying opportunity or a sign of further downside. Some attribute the weakness to South Korean market moves and concerns around AI and memory demand, while others point to the funds leverage as amplifying its volatility.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The discussion centers on shifting leadership between the Magnificent Seven and semiconductors/AI infrastructure, with traders debating whether MAGS can resume leading after a pullback. Some see renewed mega-cap strength and breakout potential, while others point to recent weakness and worry that money is rotating elsewhere.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Standard Biotools Agrees To Sell Microfluidics Business To ARCHIMED

(RTTNews) - On Monday, Standard BioTools Inc. (NASDAQ: LAB) announced that it has signed a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused on the healthcare industry...

Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?

Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders? Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 11, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Proxy and Looming Shareholder Merger Vote --VRME, VAL, LAB and FTHM

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Proxy and Looming Shareholder Merger Vote --VRME, VAL, LAB and FTHM $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Proxy and Looming Shareholder Merger Vote --VRME, VAL, LAB and FTHM PR Newswire NEW YORK, Sept. 10, 2026...

INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB

INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB PR Newswire NEW YORK, Sept. 8, 2026 NEW YORK, Sept. 8, 2026 /PRNewswire/ --Class Action...

Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 21, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--NCSM, PSBQ, LAB, and RLYB

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--NCSM, PSBQ, LAB, and RLYB $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--NCSM, PSBQ, LAB, and RLYB PR Newswire NEW YORK, July 20, 2026 NEW YORK, July 20, 2026 /PRNewswire...

Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders?

Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders? Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 15, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. Upon closing of the proposed transaction, Standard BioTools shareholders are expected to own approximately 16% of the combined company. Halper Sadeh...

Standard BioTools Signs Deal To Merge With Treeline Biosciences

(RTTNews) - Monday, Standard BioTools Inc. (LAB) announced an agreement with Treeline Biosciences, Inc., a clinical-stage biopharma company, to combine in an all-stock transaction...

Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

Standard BioTools (LAB) delivered earnings and revenue surprises of 0.00% and +13.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA.

Standard BioTools Inc

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.629
Prev Close	$0.6584
Open	$0.6577
Dividend Yield	0.00%
50-Day Moving Average	$0.7016
Beta	1.52
Avg. Volume	1.36M
PE Ratio	-2.79

52-Week High	$1.72
52-Week Low	$0.6251
Market Capitalization	$246.93M
EPS (Annual)	-$0.1963
Price to Book	0.46
Revenue Per Employee	$219,359.90

Feed

News

Sentiment

Earnings

Fundamentals

Info

LAB Fundamentals